Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Biotech
Cash-strapped Vivoryon regains China rights to kidney prospect
Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves begin to dry up.
James Waldron
Nov 5, 2026 8:28am
Roche details ph. 3 kidney disease win amid blockbuster hopes
Oct 23, 2026 1:30pm
Estuary emerges with $103M for kidney disease gene therapies
Oct 16, 2026 6:30am
CSL pays $355M to co-develop Alentis’ ph. 2-stage fibrosis drug
Oct 5, 2026 4:14am
Roche’s ph. 3 win tees up blockbuster fight with Novartis
Sep 23, 2026 3:50am
Vertex’s midstage data amplify kidney disease market opportunity
Sep 22, 2026 10:09am